Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
Primary Industries
- Drugs
- Wound Care
- Therapeutic
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 294703
NexoBridâ„¢ contains a mixture of enzymes called “concentrate of proteolytic enzymes enriched in bromelainâ€, which is extracted from the stem of the pineapple plant.
IPSCIO Record ID: 264136
“Bromelain†means the raw material derived from pineapple sterns and specially processed for the Product.
NexoBrid has been designated an orphan drug and for the treatment of severe burns. NexoBrid’s label provides that it only be used in specialized burns centers or by burn specialists
NexoBrid is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. The removal of eschar is a procedure also known as debridement. Debridement is a critical first step in the successful healing of severe burns and chronic and other hard-to-heal wounds. Under existing SOC, burn eschar may be removed either by employing certain existing topical agents that have been found to be minimally effective or that take a significantly longer period of time to work, or by resorting to non-selective surgery, which is traumatic and may result in loss of blood and viable tissue. NexoBrid’s rapid and selective debridement alleviates the known risks associated with eschar, such as infection, eventual sepsis, wound deterioration and consequential scarring, and it allows physicians to reach an informed decision on further treatment at an earlier stage by direct visual assessment of the actual burn depth. Furthermore, NexoBrid minimizes the burden associated with invasive surgical procedures, reduces the need for skin grafting and sacrifice of healthy tissue from donor sites on a patient’s body and generally results in a more favorable overall long-term patient outcome. NexoBrid has been investigated in hundreds of patients across more than 15 countries and four continents in seven completed Phase 2 and Phase 3 clinical studies
The claims of such patents are directed to a process of preparing a mixture of escharase and proteolytic enzymes and cover the underlying proteolytic mixture of escharase and proteolytic enzymes prepared by that specific process.
US Patent No 5, 830,739
This agreement pertains to the drug industry relating in the fields of severe burns as well as chronic and other hard-to-heal wounds and connective tissue disorders.
IPSCIO Record ID: 4455
Bromelain means the raw material derived from pineapple sterns and specially processed for the Product.
Australia
AU 676464B2, ( the 464B2 Patent), examined and accepted, published March 13, 1997
Europe
EP618811B1, ( the 811B1 patent), granted patent Published April 5, 2000
Finland
F1942603A the (603A application), unexamined Published August 2, 1994
Hungary
HU21641B, the (641B patent), patent specification, Published on April 28, 1998
Israel
IL103969a, (the 969A patent), accepted application Open for Inspection, published January 10, 1997
Japan
JP08508635A (the 635A application) unexamined Published September 17, 1996 (Exhibit C)
USA
US Patent No 5, 830,739 issued November 3, 1998 (Exhibit D)
